Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NQ66
UPID:
PLCB1_HUMAN
Alternative names:
PLC-154; Phosphoinositide phospholipase C-beta-1; Phospholipase C-I; Phospholipase C-beta-1
Alternative UPACC:
Q9NQ66; D3DW12; D3DW13; O60325; Q17RQ6; Q5TFF7; Q5TGC9; Q8IV93; Q9BQW2; Q9H4H2; Q9H8H5; Q9NQ65; Q9NQH9; Q9NTH4; Q9UJP6; Q9UM26
Background:
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1, also known as PLC-beta-1, plays a pivotal role in cell signaling by catalyzing the conversion of 1-phosphatidylinositol 4,5-bisphosphate into diacylglycerol and inositol 1,4,5-trisphosphate. This process is crucial for the mediation of intracellular signaling downstream of G protein-coupled receptors, impacting various cellular functions including the regulation of the endothelial barrier.
Therapeutic significance:
PLC-beta-1's involvement in Developmental and epileptic encephalopathy 12, a severe form of epilepsy, underscores its potential as a therapeutic target. Understanding the protein's role could pave the way for innovative treatments for this and possibly other related neurological disorders.